Eli Lilly Suspends Tirzepatide Makers

This is a US news story, published by Wired, that relates primarily to Zepbound news.

US news

For more US news, you can click here:

more US news

Zepbound news

For more Zepbound news, you can click here:

more Zepbound news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Wired news

For more news from Wired, you can click here:

more news from Wired

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

brand tirzepatide prescriptions

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest generic pharmaceutical drugs news, loss medication Zepbound news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

tirzepatide products

Wired

•

The Crackdown on Compounded GLP-1 Meds Has Begun

Summary

Nutrition label

64% Informative

Eli Lilly has sent cease-and-desist letters to hundreds of compounding pharmacies, telehealth companies, and medical spas making and selling “compounded” versions of tirzepatide.

The active ingredient in diabetes drug Mounjaro and weight-loss medication Zepbound was on the US Food and Drug Administration’s shortage list from December 2022 until October 2, 2024 .

When drugs in the US go into shortage, pharmacists, doctors, and licensed outsourcing facilities are permitted to "compound" copies.

Compounding trade group filed a lawsuit against the FDA claiming tirzepatide remains in short supply.

Some telehealth companies have introduced versions of the medication with other ingredients, including glycine, niacinamide, and other B vitamins.

Some compounders may try to argue that they are still permitted to produce versions with additional active ingredients.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity